BioCentury | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

...dystrophy program (see "FDA Lifts Hold on DMD Therapy" ). Dermatology companies Foamix, Menlo merge Foamix...
...a dermatology company with a portfolio that includes an approved product and three late-stage candidates. Foamix's...
...slated to launch in January. The transaction is expected to close by 2Q20, after which Foamix...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...plc (LSE:AZN; NYSE:AZN) Roxadustat Treat anemia in chronic kidney disease (CKD) patients Submit NDA YE19 Foamix...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...S.A. (Euronext:ERYP; NASDAQ:ERYP) $316.5 $316.5 Drugs encapsulated in donated red blood cells Cancer, endocrine/ metabolic Foamix...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Inc. (NASDAQ:FGEN) / AstraZeneca plc (LSE:AZN; NYSE:AZN) Roxadustat CKD-associated anemia MACE data; Submit NDA 1H19 Foamix...
BioCentury | Nov 28, 2018
Company News

Management tracks: PolarityTE and Foamix hire first chief commercial officers

...Pharmaceuticals LLC, now owned by Chinese conglomerate Sanpower Group Co. Ltd. (Nanjing, China). Dermatology company Foamix...
BioCentury | Nov 9, 2018
Clinical News

Foamix planning NDA for minocycline foam to treat rosacea

...received vehicle (p=0.0077). FMX103 was generally well tolerated with no treatment-related serious adverse events reported. Foamix...
...next half from the Phase III FX2016-13 trial of FMX103 to treat rosacea. In September, Foamix...
...agency's 505(b)(2) pathway (see “Foamix’s Minocycline Foam Meets in Third Phase III for Acne” ). Foamix...
BioCentury | Nov 7, 2018
Clinical News

Foamix planning NDA for minocycline foam to treat rosacea

...received vehicle (p=0.0077). FMX103 was generally well tolerated with no treatment-related serious adverse events reported. Foamix...
...next half from the Phase III FX2016-13 trial of FMX103 to treat rosacea. In September, Foamix...
...Foamix was up $0.11 to $4.59 on Wednesday. Jaime De Leon minocycline foam (FMX101, fxfm244, FMX-101) minocycline foam (FMX103) Foamix...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...in China YE18 Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) FMX101 Moderate to severe acne Submit NDA YE18 Foamix...
BioCentury | Sep 14, 2018
Clinical News

Foamix's minocycline foam meets in third Phase III for acne

...p<0.0001). FMX101 was generally well tolerated with no treatment-related serious adverse events reported. In 2017, Foamix...
...count endpoint (see "FMX101: Ph III Trial 04 and 05 Data" ). On Sept. 13, Foamix...
...at $6 in a follow-on underwritten by BofA Merrill Lynch, Cowen, Barclays and Cantor Fitzgerald. Foamix...
BioCentury | Sep 14, 2018
Financial News

Foamix raises $70M following Phase III acne readout

...BofA Merrill Lynch, Cowen, Barclays and Cantor Fitzgerald. The price is a tiny discount to Foamix's...
...gained $0.19 to $6.30 on Thursday, and priced the offering after market hours. On Tuesday, Foamix...
...derivative of tetracycline. Foamix was off $0.12 to $6.18 on Friday. Brian Moy minocycline foam (FMX101, fxfm244, FMX-101) Foamix...
Items per page:
1 - 10 of 62
BioCentury | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

...dystrophy program (see "FDA Lifts Hold on DMD Therapy" ). Dermatology companies Foamix, Menlo merge Foamix...
...a dermatology company with a portfolio that includes an approved product and three late-stage candidates. Foamix's...
...slated to launch in January. The transaction is expected to close by 2Q20, after which Foamix...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...plc (LSE:AZN; NYSE:AZN) Roxadustat Treat anemia in chronic kidney disease (CKD) patients Submit NDA YE19 Foamix...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...S.A. (Euronext:ERYP; NASDAQ:ERYP) $316.5 $316.5 Drugs encapsulated in donated red blood cells Cancer, endocrine/ metabolic Foamix...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Inc. (NASDAQ:FGEN) / AstraZeneca plc (LSE:AZN; NYSE:AZN) Roxadustat CKD-associated anemia MACE data; Submit NDA 1H19 Foamix...
BioCentury | Nov 28, 2018
Company News

Management tracks: PolarityTE and Foamix hire first chief commercial officers

...Pharmaceuticals LLC, now owned by Chinese conglomerate Sanpower Group Co. Ltd. (Nanjing, China). Dermatology company Foamix...
BioCentury | Nov 9, 2018
Clinical News

Foamix planning NDA for minocycline foam to treat rosacea

...received vehicle (p=0.0077). FMX103 was generally well tolerated with no treatment-related serious adverse events reported. Foamix...
...next half from the Phase III FX2016-13 trial of FMX103 to treat rosacea. In September, Foamix...
...agency's 505(b)(2) pathway (see “Foamix’s Minocycline Foam Meets in Third Phase III for Acne” ). Foamix...
BioCentury | Nov 7, 2018
Clinical News

Foamix planning NDA for minocycline foam to treat rosacea

...received vehicle (p=0.0077). FMX103 was generally well tolerated with no treatment-related serious adverse events reported. Foamix...
...next half from the Phase III FX2016-13 trial of FMX103 to treat rosacea. In September, Foamix...
...Foamix was up $0.11 to $4.59 on Wednesday. Jaime De Leon minocycline foam (FMX101, fxfm244, FMX-101) minocycline foam (FMX103) Foamix...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...in China YE18 Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) FMX101 Moderate to severe acne Submit NDA YE18 Foamix...
BioCentury | Sep 14, 2018
Clinical News

Foamix's minocycline foam meets in third Phase III for acne

...p<0.0001). FMX101 was generally well tolerated with no treatment-related serious adverse events reported. In 2017, Foamix...
...count endpoint (see "FMX101: Ph III Trial 04 and 05 Data" ). On Sept. 13, Foamix...
...at $6 in a follow-on underwritten by BofA Merrill Lynch, Cowen, Barclays and Cantor Fitzgerald. Foamix...
BioCentury | Sep 14, 2018
Financial News

Foamix raises $70M following Phase III acne readout

...BofA Merrill Lynch, Cowen, Barclays and Cantor Fitzgerald. The price is a tiny discount to Foamix's...
...gained $0.19 to $6.30 on Thursday, and priced the offering after market hours. On Tuesday, Foamix...
...derivative of tetracycline. Foamix was off $0.12 to $6.18 on Friday. Brian Moy minocycline foam (FMX101, fxfm244, FMX-101) Foamix...
Items per page:
1 - 10 of 62